Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Coronavirus
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder

  • Adam Feuerstein

By Adam Feuerstein Aug. 4, 2022

Reprints
Amgen HQ
Mark J. Terrill/AP

Amgen said Thursday that it will acquire the small drugmaker ChemoCentryx for $4 billion to obtain a newly approved medicine that treats patients with a serious autoimmune condition.

ChemoCentryx is being purchased for $52 per share, or a 116% premium to its Wednesday closing price.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Create a display name to comment

This name will appear with your comment

People with terminal cancer need to know they are…
People with terminal cancer need to know they are dying. Doctors shouldn’t withhold that information
Your questions on the new Covid vaccine boosters answered
Your questions on the new Covid vaccine boosters answered
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
Pharmalittle: Illumina faces more challenges after winning FTC case;…
Pharmalittle: Illumina faces more challenges after winning FTC case; Novo Nordisk buys Forma Therapeutics
Illumina wins case against FTC in bid to hold…
Illumina wins case against FTC in bid to hold onto early cancer detection company Grail
Listen: The anti-aging research boom, the Godfather of biotech,…
Listen: The anti-aging research boom, the Godfather of biotech, & the future of Biogen

Recommended Stories